PPA News

108 Articles found
Page 1 of 11 • Next

Posted by: Shannon Manzi on Sep 10, 2020

Access to childhood vaccines, and in turn the protection offered to the greater public health, is critical to the health and welfare of our country. PPA strongly endorses the action taken by the Secretary of Health and Human Services under the Third Amendment to Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID–19, allowing for the provision of childhood vaccines by pharmacists. PPA stands with our fellow pharmacists to ensure competency, education of the public, transparent communication and continued partnership with our provider colleagues.

Shannon Manzi, PharmD, BCPPS, FPPA
President, Pediatric Pharmacy Association



Posted by: Matthew Helms on Jun 2, 2020


On Thursday, May 28, 2020 after thoughtful consideration, the Board voted to shift our 2020 Fall Conference and BCPPS Review and Recertification Course to a virtual format. Many factors contributed to our decision. 

The most important contributing factor is the health of our members and staff during the COVID-19 pandemic. We also recently surveyed you, our members, to ask about the effects the pandemic has had on your employers and your personal feelings about traveling at this time.

The vast majority of our members work in institutions that have enforced indefinite business-related travel bans or restrictions. Some of you may not be able to travel for the rest of the year. Also, most of our members' employers have already or will experience a reduction in their travel budgets for the foreseeable future. In addition, and maybe most importantly, survey participants indicated they are uncomfortable traveling to an in-person conference even if the challenges listed above were mitigated. 

We are also concerned about the logistical challenges and liability of conducting an in-person event during a global pandemic. 

While we were hopeful that we could offer a hybrid event, the uncertainty is too great to plan any in-person gathering in good conscience. While we are disappointed that will not meet in-person this year, we are not disheartened, and we look forward to working on offering an interactive, 100% virtual event. 

We learned much from conducting our Annual Meeting virtually. We have listened to the feedback of the 500+ participants, and we will be improving and adjusting the Fall Conference experience to make it even better. Here is what we have in store for the Fall Conference this year: 

  1. Twenty hours (20) of continuing pharmacy education in the areas of GI/Nutrition, General Pediatrics and Preceptor Development, including eight (8) hours of BCPPS recertification credit. 
  2. Poster Session 
  3. Residency Showcase 
  4. Helms Award Lecture
  5. Yaffe Award Lecture
  6. Lobby Lunch Sessions (an opportunity each day to interact with your friends and colleagues virtually). 
  7. Exhibitor Theaters
  8. And don’t forget, the 20-hour BCPPS Review and Recertification Course


We have reduced our registration fees (up to 30%) to make our Conference even more accessible in the light of your current budget challenges. If you are an individual member of PPA, you can register for the entire conference for $300. That's $15 per credit hour. And it’s even more affordable for residents and students! Also, we have eliminated regular and late registration fees. Every rate is an early bird rate! We, of course, encourage you to register early.

You can still submit YOUR proposal(s) and/or abstract(s) to be considered for the Fall Conference. 

Call for Education Program Proposals - All educational programs at PPA are sourced by our members, who submit proposals to be considered by the Education Committee.

We call upon our members to submit ideas for sessions in GI/Nutrition, General Pediatrics, and Preceptor Development or Scholarship. You may submit a full proposal (which includes title, speakers, learning objectives, learning methods, and educational needs assessment), or you can submit a partial proposal (which includes suggested title, speakers, and learning objectives). Please note that all proposals will be considered for our PPA-U BCPPS recertification program.

The proposal deadline is June 26, 2020. Submit Proposal

Call for Abstracts. All practitioners, investigators, post-doctoral trainees, and students in the field of pediatric clinical pharmacy, whether members of PPA or not, are invited to submit abstracts of papers to be considered for platform or poster presentation at the Fall Conference. Poster Presentations are informal discussions of current projects in pharmacy practice with meeting attendees. It is your opportunity to share your research or successful programs that have worked in pediatric healthcare systems, and to pick up ideas from others.

NOTE FOR DEFERRED ANNUAL MEETING ABSTRACTS: You must re-submit your abstract using the Fall Conference Abstract submission site.

The abstract deadline is June 26, 2020. Submit Abstract

We appreciate your input as members of PPA and look forward to coming together as a community and professional family for the 2020 PPA Fall Conference and BCPPS Review and Recertification Course

Thank you for your ongoing strong commitment and dedication to your patients, family, and communities. You are what make PPA and the profession of pediatric pharmacy AWESOME!


Hanna Phan, PharmD, FCCP, FPPA
President (2019-2020)

Matthew Helms, MA, CAE
Executive Director


Posted by: Matthew Helms on Oct 7, 2020

This communication was prepared by Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA.

On September 29, 2020, the U.S. Food and Drug Administration (FDA) approved efficacy supplements for SIMPONI ARIA for patients 2 years of age and older for the treatment of active psoriatic arthritis (PsA) or active polyarticular juvenile idiopathic arthritis (pJIA). In addition to the treatment of children ages 2 years and older with active pJIA or active PsA, SIMPONI ARIA is approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate, active PsA, or active ankylosing spondylitis (AS).

The approved recommended dosage of SIMPONI ARIA is:

  • Adult patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: 2 mg/kg intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter.
  • Pediatric patients with polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: 80 mg/m2 intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter.

Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA. Discontinue SIMPONI ARIA if a patient develops a serious infection or sepsis. Perform test for latent TB; if positive, start treatment for TB prior to starting SIMPONI ARIA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI ARIA is a member.

Additional information regarding dosage and administration as well as warnings and precautions about serious infection, invasive fungal infections, hepatitis B reactivation, malignancies, congestive heart failure, demyelinating disorders, autoimmunity, use with anakinra or abatacept, switching between biological disease modifying antirheumatic drugs, hematologic cytopenias, vaccinations/therapeutic infectious agents, or hypersensitivity reactions can be found in the full prescribing information linked below.

Mechanism of Action (MOA), Pharmacokinetics (PK), and Pharmacodynamics (PD)

MOA: Golimumab is a human monoclonal antibody that binds to both the soluble and transmembrane bioactive forms of human TNFα.

General PK: Golimumab exhibited approximately dose-proportional pharmacokinetics in patients with RA over the dose range of 0.1 to 10.0 mg/kg (0.05 to 5 times the approved recommended adult dosage) following a single intravenous dose.

Absorption: Following a single intravenous administration of 2 mg/kg SIMPONI ARIA, a mean Cmax of 44.4 ± 11.3 mcg/mL was observed in patients with RA. Data directly comparing 2 mg/kg intravenous administration and 50 mg subcutaneous administration are not available.

Distribution: Following a single intravenous administration of 2 mg/kg SIMPONI ARIA, the mean volume of distribution was estimated to be 115 ± 19 mL/kg in healthy subjects, and 151 ± 61 mL/kg in patients with RA. The volume of distribution of golimumab may indicate that golimumab is distributed primarily in the circulatory system with limited extravascular distribution.

Elimination: Following a single intravenous administration of 2 mg/kg SIMPONI ARIA, the systemic clearance of golimumab was estimated to be 6.9 ± 2.0 mL/day/kg in healthy subjects and 7.6 ± 2.0 mL/day/kg in patients with RA. The mean terminal half-life was estimated to be 12 ± 3 days in healthy subjects and the mean terminal half-life in RA patients was 14 ± 4 days.

PD: Following treatment with SIMPONI ARIA in patients with RA, decreases from baseline were observed in tissue inhibitor of metalloproteinase-1 (TIMP-1), matrix metalloproteinase-1 (MMP-1), matrix metalloproteinase-3 (MMP-3), resistin, interleukin-6 (IL-6), macrophage inflammatory protein-1 (MIP-1b), vascular endothelial growth factor (VEGF), serum amyloid A (SAA), S100A12, and high sensitivity C-Reactive protein (hsCRP). Conversely, increases from baseline were observed in tartrate-resistant acid phosphatase (TRAP-5b). The clinical relevance of this information is not known.

Immunogenicity: Antibodies to golimumab were detected in 13 (3%) golimumab-treated patients following IV administration of SIMPONI ARIA in combination with MTX through Week 24 of Trial RA, of which all were neutralizing antibodies. Through approximately 6 months, the incidence of antibodies to golimumab for RA, PsA, AS, and pJIA was 21%, 19%, 19% and 31%, respectively. Where tested, approximately one-third to one-half were neutralizing. Patients with RA, PsA, AS and pJIA who developed antibodies to golimumab generally had lower trough steady-state serum concentrations of golimumab. The immune response effect on golimumab clearance in patients with JIA with active polyarthritis was comparable to adults with RA.

Drug Interactions

Methotrexate: SIMPONI ARIA should be used with MTX for the treatment of RA. Following IV administration, concomitant administration of methotrexate decreases the clearance of SIMPONI ARIA by approximately 9% based on population pharmacokinetics (PK) analysis. In addition, concomitant administration of methotrexate decreases the SIMPONI ARIA clearance by reducing the development of antibodies to golimumab.

Biologic Products for RA, PsA, AS, and pJIA: An increased risk of serious infections has been seen in clinical RA studies of other TNF-blockers used in combination with anakinra or abatacept, with no added benefit; therefore, use of SIMPONI ARIA with other biologic products, including abatacept or anakinra, is not recommended. A higher rate of serious infections has also been observed in RA patients treated with rituximab who received subsequent treatment with a TNF-blocker. The concomitant use of SIMPONI ARIA with biologics approved to treat RA, PsA, AS, and pJIA is not recommended because of the possibility of an increased risk of infection.

Live Vaccines/Therapeutic Infectious Agents: Live vaccines should not be given concurrently with SIMPONI ARIA. Therapeutic infectious agents should not be given concurrently with SIMPONI ARIA. Infants born to women treated with SIMPONI ARIA during their pregnancy may be at increased risk of infection for up to 6 months. Administration of live vaccines to infants exposed to SIMPONI ARIA in utero is not recommended for 6 months following the mother’s last SIMPONI ARIA infusion during pregnancy.

Cytochrome P450 Substrates: The formation of CYP450 enzymes may be suppressed by increased levels of cytokines (e.g., TNFα) during chronic inflammation. Therefore, it is expected that for a molecule that antagonizes cytokine activity, such as golimumab, the formation of CYP450 enzymes could be normalized. Upon initiation or discontinuation of SIMPONI ARIA in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed.

Use in Specific Populations

No formal study of the effect of renal or hepatic impairment on the PK of golimumab was conducted.

Body Weight: Following intravenous administration, patients with higher body weight tended to have slightly higher serum golimumab concentrations than patients with lower body weights when golimumab was administered on a mg/kg (body weight) basis. However, based on population PK analysis, there were no clinically relevant differences in golimumab exposure following intravenous administration of 2 mg/kg SIMPONI ARIA in adult patients across a range of different body weights. Consistent with the intravenous data in adult patients with RA, population pharmacokinetic analyses for intravenous SIMPONI ARIA in pJIA revealed that there were no clinically relevant differences in golimumab exposure following intravenous administration of 80 mg/m2 SIMPONI ARIA in pediatric patients across a range of age and different body weights. The immune response effect on golimumab clearance in patients with JIA with active polyarthritis was comparable to adults with RA.

Pediatrics: When 80 mg/m2 SIMPONI ARIA was administered intravenously to patients with JIA with active polyarthritis at weeks 0, 4 and every 8 weeks thereafter, serum concentrations reached steady-state by Week 12. With concomitant use of MTX, treatment with 80 mg/m2 SIMPONI ARIA resulted in a mean steady-state trough serum golimumab concentration of approximately 0.5 ± 0.4 mcg/mL and a mean steady-state AUC of 425 ± 125 mcg∙day/mL in patients with JIA with active polyarthritis. Overall, the observed steady-state golimumab trough concentrations in patients with JIA with active polyarthritis were within the range of those observed for adult RA and PsA after administration of SIMPONI ARIA.

Efficacy and Safety

Psoriatic Arthritis: The efficacy of SIMPONI ARIA in pediatric patients with PsA is based on the pharmacokinetic exposure and extrapolation of the established efficacy of SIMPONI ARIA in adult PsA patients. The efficacy and safety of SIMPONI ARIA were evaluated in a multicenter, randomized, double-blind, placebo-controlled trial in 480 patients ≥ 18 years of age with active psoriatic arthritis despite NSAID or DMARD therapy. Previous treatment with a biologic was not allowed. The primary endpoint was the percentage of patients achieving an American College of Rheumatology (ACR) 20 response at Week 14.

Polyarticular Juvenile Idiopathic Arthritis: The efficacy of SIMPONI ARIA in pediatric patients with pJIA is based on the pharmacokinetic exposure and extrapolation of the established efficacy of SIMPONI ARIA in RA patients. Efficacy of SIMPONI ARIA was also assessed in a multicenter, open-label, single-arm study in 127 children (2 to < 18 years of age) with JIA with active polyarthritis despite treatment with MTX for at least 2 months. Efficacy was assessed as supportive endpoints through Week 52. Additional information regarding the efficacy trials can be found in the full prescribing information linked below.

Rheumatoid Arthritis: The efficacy and safety of SIMPONI ARIA were evaluated in one multicenter, randomized, double-blind, controlled trial in 592 patients ≥ 18 years of age with moderately to severely active RA despite concurrent MTX therapy and had not previously been treated with a biologic TNF-blocker. The primary endpoint in Trial RA was the percentage of patients achieving an ACR 20 response at Week 14.

Ankylosing Spondylitis: The efficacy and safety of SIMPONI ARIA were evaluated in a multicenter, randomized, double-blind, placebo-controlled trial in 208 patients ≥ 18 years of age with active ankylosing spondylitis (AS) and inadequate response or intolerance to NSAIDs. The primary endpoint was the percentage of patients achieving an Assessment in Ankylosing Spondylitis (ASAS) 20 response at Week 16.

Additional information regarding the efficacy trials can be found in the full prescribing information linked below.

The most common adverse reactions (incidence ≥ 3%) are: upper respiratory tract infection, alanine aminotransferase increased, viral infection, aspartate aminotransferase increased, neutrophil count decreased, bronchitis, hypertension, and rash.

Full prescribing information is available at https://go.usa.gov/xG6Zf.

Visit Drugs@FDA at http://go.usa.gov/cMsjT for prescribing and patient information, approval letters, reviews and other information for FDA-approved drug products, which are often available shortly following approval.

A non-comprehensive list of examples of clinical substrates, inhibitors and inducers for metabolic and transporter system related interactions may be found at https://go.usa.gov/xXY9C.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System by completing a form online at https://www.fda.gov/safety/medwatch/default.htm, by faxing (1-800-FDA-0178), or by mailing the postage-paid address form provided online, or by telephone (1-800-FDA-1088).

The Office of Clinical Pharmacology (OCP) is pleased to offer the e-mail subscription service Clinical Pharmacology Corner. This is a free service from FDA to provide occasional updates from OCP regarding newly approved therapies, new regulatory and scholarly publications, upcoming events and other items of interest. Subscribe today at https://updates.fda.gov/subscriptionmanagement (note: this link does not work with Internet Explorer) and select Clinical Pharmacology Corner under Drugs.


We always welcome your thoughts regarding the format, content, and utility of this communication. Comments may be sent via email to ocp@fda.hhs.gov.

This communication was prepared by Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA.

Posted by: Shannon Manzi & Matthew Helms on Sep 24, 2020

Hot off the press!  We are happy to share the Pharmacists as Childhood Immunizers Talking Point document created by our Advocacy Committee.  It is important to use our expertise to help support our colleagues who are less comfortable with pediatric care, especially when it comes to vaccinating children.  Education will be a key component in ensuring the gains we are making moving our profession forward will be sustained. 

Please see the document here

Posted by: Lea Eiland on Jun 15, 2020


Congratulations to the 2020-2021 SIG Chairs and Vice Chairs. 





Amanda Capino

Sarah Smith

Ambulatory Care

Kevin Lonabough and Hannah Pratt



Josh Robinson

Amy Kiskaddon

Critical Care

Elizabeth Beckman

Melissa Gervase

Drug Information and Technology

Paul Paratore

Karl Gumpper

Emergency Medicine

Jenny Steinbrenner

Mary Riedy

General Pediatrics

Mindy Parman

Kristi Higgins


Lola Afolabi

Cait Stehling


Andrew Clark

Jenn Le

Infectious Disease

Sarah Parsons

Mike Raschka

Clinical Leadership/Practice Managers

Courtney Sweet

Sierra Stauber

Medication Safety

Hyun Kim

Casey Moore


Jenni Barnes

Deb Bondi

Neurology (NEW)

Renad Abu-Sawwa

Justin Cole

New Practitioner

Nicole Omecene

Jen Hamner

Obstetrics/Women's Health

Noelle Leung


Public Health (NEW)

Cameron McKinzie

Thomas Laudone


Katie Hobart


Residency Program Directors

Kelly Bobo

Kelly Steidl

Do you want to participate in activities and learn from other pediatric pharmacists of similar interest as you? If so, sign up as a member of a PPA Special Interest Group (SIG) today!

PPA has 19 SIGs, with two being NEW this year! Membership in SIGs is complimentary to all PPA members. To join a Special Interest Group eCommunity, Update your Profile via your myPPA page. You sign yourself up via the PPA website. There is no limit to how many you join and no additional charge to join a SIG.

We hope you all will join the SIGs of your interest and network with others!

If you have any questions related to the SIGs, please feel free to contact us.

Thank you!

Lea Eiland, SIG Coordinator Chair
Kalen Manacso, SIG Coordinator Chair-Elect



Posted by: Matthew Helms on Jun 2, 2020

Brian Eugene Baldwin, 89, of Centennial, CO passed away at Holly Creek Senior Living Community on May 25, 2020.

Mr. Baldwin was an early supporter of the Pediatric Pharmacy Association (previously the Pediatric Pharmacy Advocacy Group). 

Mr. Baldwin had a significant impact on pediatrics. His first company, MPL, inc., founded in 1958 in Chicago, IL was a pioneer in development of inexpensive disposable hypodermic needles. In 1975 Brian co-founded Baxa Corporation, originally located in Northbrook, IL. In 1981, he moved with the company to Colorado, where he would live the remainder of his life. Baxa grew in the next 30 years to have over 700 employees, serving hospitals in over 65 countries. Several of his inventions were key to the success of the company, which specialized in the safe handling and preparation of IV and liquid medications. Brian's inventions were recognized for preventing medication errors and saving lives. 


Posted by: Hanna Phan on May 3, 2020


For those able to join on at our 1st virtual conference, the 29th Annual Meeting, thank you for taking time from your busy schedules to participate in quality educational sessions lead by our amazing pediatric pharmacy expert members.

I wanted to take a moment to recognize our 2020 Fellows and Award Recipients – CONGRATULATIONS!!

2020 Fellow (FPPA)

  • Dr. Jeffery Low, Children’s Hospital at Dartmouth 
  • Dr. Brooke Gildon, Southwestern Oklahoma State University

2020 Presidential Citation Award --- “The KIDs List Team”

  • Dr. Rachel Meyers, Rutgers University
  • Dr. Jennifer Thackary, Memorial Sloan Kettering Cancer Center
  • Dr. Kelly Matson, University of Rhode Island
  • Dr. Christopher McPherson, St Louis Children’s Hospital
  • Dr. Lisa Lubsch, Southern Illinois University Edwardsville
  • Dr. Robert Hellinga, University of New Mexico Hospital
  • Dr. David Hoff, Children’s Hospitals and Clinics of Minnesota

2020 Spirit of PPA Award

  • Dr. Jennifer Hamner, Colorado Children’s
  • Dr. Norm Fenn, U of Texas-Tyler
  • Dr. Elizabeth Boucher, Concord Hospital

2020 Outstanding Original Research Paper

  • Dr. Bethany Chalk, Johns Hopkins Hospital

2020 Christensen Memorial Young Investigator Award

  • Dr. Amy Kiskaddon, Johns Hopkins All Children’s Hospital

2020 Best Practice Award

  • Dr. Julia Muzzy Williamson, North Dakota State University (presenter)
  • Dr. M Kari Casas, Sanford Children’s Broadway Clinic
  • Dr. May Kamleh, Health Economics and Outcomes Research
  • Dr. Mohamed Mohamed, Sanford Children’s Hospital

2020 Scholarship in Teaching Award

  • Dr. Lea Eiland, Auburn University (presenter)
  • Dr. Allison Chung, Auburn University
  • Dr. Julaine Fowlin, Auburn University

2020 Scientific Platforms

  • Dr. Jeremy Stultz, University of Tennessee
  • Hemisha Patel and Alysia Leung (PharmD candidates), Virginia Commonwealth University

2020 Student Investigator Award

  • Margaret Morales, Hampton University

2020 John Dice Scholarship

  • Erica Terry, University of Wisconsin
  • Sonya Barich, University of Colorado

Thank you to the following PPA Board of Director Members, who will be completing their terms in June 2020, for their dedication and service to PPA:

  • Immediate Past President - Dr. Miranda Nelson
  • Director-at-Large – Dr. Bob John
  • Director-at-Large – Dr. Tara Higgins

I also would like to express my gratitude to, our PPA staff, committees, speakers, moderators, poster and resident presenters -– for your patience, hard work, and passion for pediatric pharmacy. Your efforts are what made this virtual “first” for our association, and our association overall – AMAZING. We are a close and caring community and we should be proud to be part it.

And, THANK YOU from bottom my heart, all PPA members, for the opportunity to serve as your 2019-2020 President. It has truly been an honor and privilege to serve PPA and our profession. I am truly grateful for the friendships, relationships, and collaborations this community provides.

With deep gratitude,

Hanna Phan, PharmD, FCCP, FPPA
2019-2020 PPA President



Posted by: Matthew Helms on Mar 25, 2020

Our friends at the Society of Infectious Diseases Pharmacists distributed the following message to their members. PPA agrees with the content of the letter and we encourage our members to submit their concerns to States Board of Pharmacy.

Please see below: 

During times of crisis such as COVID-19, our elected officials and state boards of pharmacy have the power to enact regulations so that pharmacists are able to provide increased care and have more opportunity to further protect the public health and safety.   

One pressing issue in which pharmacists can assist is the recent surge in outpatient prescription of medication that have shown limited efficacy in the treatment of COVID-19, including chloroquine, hydroxychloroquine, mefloquine, and azithromycin. While there are currently no approved treatments for COVID-19, there have been several reports that prescriptions for these medications are being issued by prescribers in the community without indication, for persons without COVID-19 disease, often in large quantities with a high number of refills.  

There is concern for hoarding of these medications which is resulting on a shortage for admitted patients with laboratory diagnosed COVID-19, or for their intended indication (i.e., hydroxychloroquine for patients with lupus).  Several of these medications, including hydroxychloroquine and azithromycin, are now on shortage or are out-of-stock by distributors and may not be available for patients with COVID-19 disease.

At time of this communication, at least five states at this time have enacted emergency regulations to institute changes to help pharmacists limit prescriptions for these drugs and to reserve them for patients with COVID-19 patients who might need them most at this time.

Ohio & Nevada: Restrict the dispensing or sale of chloroquine and hydroxychloroquine to those with a prescription for the treatment of COVID-19; and limit quantity dispensed to a14-day supply with no refills 

Idaho: Restrict the dispensing of chloroquine and hydroxychloroquine to those with a prescription with a written diagnosis consistent with evidence for its use; and limit quantity dispensed to a14-day supply with no refills 

Texas: Restrict the dispensing of chloroquine, hydroxychloroquine, mefloquine, and azithromycin to those with a prescription with a written diagnosis consistent with evidence for its use from the prescriber; and limit quantity dispensed to a14-day supply with no refills 

Rhode Island: New regulations to allow off-label prescribing to treat COVID-19 only if the prescription meets several requirement inducing indicating an applicable diagnosis code and indicating a telephone number for the provider to address questions related to dose and treatment, and documentation of clinical rationale for treatment

Several other states and boards of pharmacy are expected to enact emergency regulation to limit who can be prescribed of these treatments and how much, in the next few days.  

We encourage you to send a letter to your boards of pharmacy / departments of health, to limit use of these medications and save them for patients with laboratory diagnosed COVID-19.  Please use this template for your letter.


The Society of Infectious Diseases Pharmacists Board of Directors


Posted by: Matthew Helms on Mar 12, 2020

The 28th Annual PPA Meeting is going virtual!

We have been closely monitoring the CDC and WHO reports regarding the spread of COVID-19. Our Board of Directors has met and based on considerations for individual health, public health, and the financial health of our association, we believe that change to a virtual format for our 29th Annual Meeting is the most appropriate course of action.

While the schedule of events and delivery methods for the meeting have changed, we will still provide our core educational content in hematology, oncology, and neonatal intensive care from April 29-May 3, 2020. We will also be conducting an online/virtual poster session and residency presentations.

Please stay tuned for a revised agenda coming soon.

Over the coming weeks you will be receiving more information about the virtual conference. In the meantime, we have included brief Q&A (below) for you to consider. We hope these answers provide some direction and clarity as we move forward.

We will be holding a virtual Town Hall on Tuesday, March 17, 2020 at 4:00 pm Eastern (3:00 pm Central) to answer your questions regarding our Annual Meeting. Join from PC, Mac, Linux, iOS or Android: https://zoom.us/j/463995074.

Thank you all for your ongoing contributions and passion for PPA. Although these are challenging times, we are enthusiastic about our upcoming conference, and look forward to “seeing” you there!

We appreciate your patience and understanding!


Hanna Phan, PharmD, FPPA
PPA President

Matthew Helms, MA, CAE
PPA Executive Director


I want to attend the virtual meeting. What do I do now?

If you are registered for the conference, and still want to attend the Annual Meeting, you are all set. You will be sent login/call-in instructions in a few weeks. Your experience will be different of course. However, you will be able to take advantage of the same core programming, posters, and platform presentations. You will be able to receive the same ACPE-accredited and BPS-approved continuing education. The requirements and process for receiving CPE and BCPPS credits will not change.

If you have not registered for the conference, and you can now attend, please go to the Conference website for more information. https://www.ppag.org/?pg=events&evAction=showDetail&eid=77786&evSubAction=listAll

I am a student. Will PPA conduct the student conference online, too?

Yes. If you are registered for the conference, and still want to attend the Student program, you are all set. You will be sent login/call-in instructions in a few weeks. While the experience will be different, the content will be the same.

I am presenting a poster. What do I do now?

PPA will be hosting a Virtual Poster Session on Friday, May 1, 2020 at 10:00 AM – 11:00 AM eastern time. You will be able to present your poster from your home or office at that time. If you are registered for the conference, and your poster has been accepted, you will receive emailed instructions on how to upload your poster to the system. Note: your poster must fit inside a PPT slide.

I want to attend the Virtual Poster Session. What do I do now?

If you are registered for the Annual Meeting, you will be sent emailed instructions about how to login to and navigate the Virtual Poster Session.

Will PPA virtually present Best Practice Award, Teaching Award, and Scientific Platform Presentations?

Yes, although the exact times of the presentations have changed. Please refer to our revised agenda.

I am a Resident schedule to present during the Annual Meeting. What do I do now?

If you are presenting your residency project, things will be changing a lot! The Bruce Parks Memorial Residency Project Presentations will be held on Friday, May 1, 2020 from 12:30-3:30 pm eastern time, and will become a Virtual Poster Session combined with your oral presentation. We have been in contact with ASHP’s Accreditation Services Office to make sure that our changes meet the R2.2.6 accreditation objective.

We will be sending an email with a modified schedule and specific instruction on what to do next.

What is the refund policy for registration?

If you cannot attend the virtual meeting and have already registered for the meeting, you can request a refund. You also have the option to transfer any balance to a future PPA meeting. Please contact us at membership@pediatricpharmacy.org.

Can I get reimbursed for transportation and hotel cost or penalties?

No. We are unable to provide refunds for travel expenses. Please work directly with your airline and the conference hotel at 757-763-6200 to cancel your reservations. If you purchased travel insurance, please contact your provider for information and next steps. 



Posted by: Matthew Helms on Feb 28, 2020

M. Petrea Cober, PharmD, BCNSP, BCPPS, FASPEN, attended the University of Tennessee, College of Pharmacy in Memphis, Tennessee. She completed her PGY1 Pharmacy Residency at Penn State Milton S. Hershey Medical Center in Hershey, Pennsylvania, and her PGY2 Pharmacy Residency in Pediatrics at the University of Michigan Hospitals and Health System in Ann Arbor, Michigan. She is currently the Clinical Coordinator - Neonatal Intensive Care Unit and PGY1 Residency Program Director at Akron Children's Hospital where she provides clinical services and precepts pharmacy students, PGY1 pharmacy residents, and PGY3 medical pediatric residents. She is also the Section Lead for Specialty Care and an Associate Professor in the Department of Pharmacy Practice at Northeast Ohio Medical University (NEOMED). Her didactic teaching is in the areas of pediatrics, women’s health, and nutrition. Dr. Cober's expertise is in pediatric pharmacotherapy, nutrition, ethanol lock therapy, and management of patients with intestinal failure.

Dr. Cober served as the Chair of the Webinar Education Committee from 2017-2019 and is the current Chair of the Education Committee. She is active in the Academia, GI/Nutrition, Neonatology, and Residency Program Directors SIGs.

Jeremy Stultz, PharmD is an Assistant Professor at the University of Tennessee Health Science Center and practices as an Antimicrobial Stewardship Pharmacist at Le Bonheur Children’s Hospital in Memphis, TN. He received a Doctor of Pharmacy degree from the University of Pittsburgh School of Pharmacy and completed a PGY-1 Residency at Le Bonheur and a 2-year Pediatric Pharmacotherapy Fellowship at The Ohio State University and Nationwide Children’s Hospital in Columbus, Ohio. He was a faculty member at the Virginia Commonwealth University School of Pharmacy before returning to Tennessee. He has authored over 20 peer-reviewed journal publications focused primarily on pediatric infectious diseases, computerized clinical decision support, and medication safety.

Dr. Stultz attended his first PPA Annual Meeting as a student. Since that time, he has presented multiple times PPA meetings. Dr. Stultz has served as PPA Research Committee Chair, and helped form the Pediatric Pharmacy Association Practice Based Research Network.



Page 1 of 11 • Next